Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Parmodia, Canalia Climb GP Recollection Ranking in August: Anterio
October 25, 2017
- Sumitomo Dainippon Joins Forces with Nobel Laureate to Tackle AMR Infections
October 25, 2017
- Expanded Aducanumab Collaboration Will Be a Plus for Other Alzheimer’s Pipelines: Eisai CEO
October 25, 2017
- Mitsubishi Tanabe Trims Forecast on Sluggish Invokana Royalties
October 25, 2017
- BMS, Pfizer Launch Japan Clinical Research for Atrial Fibrillation Detection
October 24, 2017
- Eisai Opts to Codevelop Biogen’s Aducanumab; New MS Copromotion Scheme Sealed
October 24, 2017
- Shionogi Ups Earnings Outlook on Milestone Scheme Change
October 24, 2017
- AZ’s Olaparib Filed for Breast Cancer in 2nd Submission
October 24, 2017
- Mitsubishi Tanabe to Focus on US Approval for VLP Seasonal Flu Vaccine; Aims at 100 Billion Yen Sales for Vaccine Business by FY2030
October 24, 2017
- Harvoni Hits 96% SVR12 Rate in Japanese Genotype 2 Hep C Patients
October 23, 2017
- Romosozumab Shows Consistent Efficacy, Safety in Japanese Osteoporosis Patients: Amgen Astellas
October 23, 2017
- Astellas Inks Collaboration with Universal Cells to Develop Novel Cell Therapy
October 23, 2017
- Seebri Neohaler Now Available in the US: Sunovion
October 23, 2017
- Lonsurf Earns Priority Status in Canada: Taiho
October 23, 2017
- Topical Sirolimus, 1st Sakigake-Designated Drug, Filed in Japan: Nobelpharma
October 23, 2017
- Kaketsuken Mum on Reported Biz Transfer to Kumamoto Consortium-Led Firm
October 20, 2017
- Mitsubishi Tanabe’s NeuroDerm Acquisition Completed
October 20, 2017
- LEO Pharma Japan to Set Up Stand-Alone Sales Force in 5 Years, Eyes 100 Reps
October 20, 2017
- Takeda’s Entrepreneurship Scheme Attracts 30 Proposals
October 20, 2017
- Boehringer, Nagoya City Univ. Collaborate on Diabetic Retinopathy Research
October 19, 2017
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…